TY - JOUR
T1 - Delivery of viral vectors to tumor cells
T2 - Extracellular transport, systemic distribution, and strategies for improvement
AU - Wang, Yong
AU - Yuan, Fan
N1 - Funding Information:
The authors thank Dr Chuan-Yuan Li for scientific discussion. The work is supported in part by a grant from the National Science Foundation (BES-9984062).
PY - 2006/1
Y1 - 2006/1
N2 - It is a challenge to deliver therapeutic genes to tumor cells using viral vectors because (i) the size of these vectors are close to or larger than the space between fibers in extracellular matrix and (ii) viral proteins are potentially toxic in normal tissues. In general, gene delivery is hindered by various physiological barriers to virus transport from the site of injection to the nucleus of tumor cells and is limited by normal tissue tolerance of toxicity determined by local concentrations of transgene products and viral proteins. To illustrate the obstacles encountered in the delivery and yet limit the scope of discussion, this review focuses only on extracellular transport in solid tumors and distribution of viral vectors in normal organs after they are injected intravenously or intratumorally. This review also discusses current strategies for improving intratumoral transport and specificity of viral vectors.
AB - It is a challenge to deliver therapeutic genes to tumor cells using viral vectors because (i) the size of these vectors are close to or larger than the space between fibers in extracellular matrix and (ii) viral proteins are potentially toxic in normal tissues. In general, gene delivery is hindered by various physiological barriers to virus transport from the site of injection to the nucleus of tumor cells and is limited by normal tissue tolerance of toxicity determined by local concentrations of transgene products and viral proteins. To illustrate the obstacles encountered in the delivery and yet limit the scope of discussion, this review focuses only on extracellular transport in solid tumors and distribution of viral vectors in normal organs after they are injected intravenously or intratumorally. This review also discusses current strategies for improving intratumoral transport and specificity of viral vectors.
UR - http://www.scopus.com/inward/record.url?scp=33644988908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644988908&partnerID=8YFLogxK
U2 - 10.1007/s10439-005-9007-2
DO - 10.1007/s10439-005-9007-2
M3 - Article
C2 - 16520902
AN - SCOPUS:33644988908
SN - 0090-6964
VL - 34
SP - 114
EP - 127
JO - Annals of Biomedical Engineering
JF - Annals of Biomedical Engineering
IS - 1
ER -